Sanj K. Patel - Apr 7, 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role: CHAIRMAN & CEO, Director
Signature: /s/ Madelyn Zeylikman, Attorney-in-Fact
Stock symbol: KNSA
Transactions as of: Apr 7, 2025
Transactions value $: -$97,993
Form type: 4
Date filed: 4/9/2025, 04:44 PM
Previous filing: Apr 3, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KNSA	Class A Ordinary Share	Options Exercise		+9.99K	+10.92%		102K	Apr 7, 2025	Direct	F1
transaction	KNSA	Class A Ordinary Share	Tax liability	-$98K	-4.83K	-4.76%	$20.28	96.7K	Apr 7, 2025	Direct
holding	KNSA	Class A Ordinary Share						110K	Apr 7, 2025	Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KNSA	Restricted Share Unit	Options Exercise	$0	-9.99K	-50%	$0.00	9.99K	Apr 7, 2025	Class A Ordinary Share	9.99K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2	The RSUs vest over a four-year period, with 25% of the RSs vesting on the yearly anniversary of the grant date, April 7, 2022.